Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007597 | 0.94 | USP30 (0.47) | SCN3APKMTDP1MEN1KMT2A | |
| SCHEMBL13007613 | 0.89 | RXFP1 (0.45) | SCN3ATDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1858135 | 0.88 | KMT2A (0.57) | SCN3AMEN1KMT2ACA12CA1 | |
| SCHEMBL1868493 | 0.85 | NPC1 (0.61) | SCN3APKMMEN1KMT2AALDH1A1 | |
| SCHEMBL11959666 | 0.83 | PKM (0.65) | SCN3APKM | |
| SCHEMBL11959670 | 0.83 | NPC1 (0.50) | PKMMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1860725 | 0.82 | NPC1 (0.52) | SCN3APKMMEN1KMT2AALDH1A1 | |
| SCHEMBL11959668 | 0.80 | NPC1 (0.49) | PKMMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8236251 | 0.80 | PKM (0.43) | SCN3APKMMEN1KMT2AALDH1A1 | |
| SCHEMBL13061291 | 0.78 | NPC1 (0.50) | PKMMEN1KMT2AALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855220-B2 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-21 | — | — | US | disclosed |
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203130-A1 | Bicyclic derivatives as modulators of voltage gated ion channels | TRPV1, TRPV2, TRPV3 | SCN3A 46/4885PKM 2850/4885TDP1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.